The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicentre, open-label phase II study of irinotecan, capecitabine, and oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
 
Arthur Gregory Ang Lui
Speakers' Bureau - Roche
 
Karen E. Mulder
Consulting or Advisory Role - LEO Pharma; Novartis
Research Funding - Amgen (Inst); Bayer (Inst); Roche (Inst); Sanofi (Inst)
 
Christine Brezden-Masley
Honoraria - Roche
Consulting or Advisory Role - Roche
Research Funding - Roche
 
Michael M. Vickers
Consulting or Advisory Role - Amgen; Celgene; Ipsen; Lilly
Speakers' Bureau - Amgen
 
Jose Gerard Monzon
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche
 
Hagen F. Kennecke
Honoraria - Amgen; Ipsen; Novartis; Sanofi
Travel, Accommodations, Expenses - Novartis; Sanofi
 
Rakesh Goel
No Relationships to Disclose
 
Sunita Ghosh
No Relationships to Disclose
 
Horia Marginean
Honoraria - Celgene; Sanofi
Consulting or Advisory Role - Celgene; Sanofi
 
Larissa Joy Vos
No Relationships to Disclose
 
SeeSee Juliana Raynard
No Relationships to Disclose
 
Kristine Lee Young
No Relationships to Disclose
 
Anthony L.A. Fields
No Relationships to Disclose
 
Jean Alfred Maroun
No Relationships to Disclose
 
Jennifer L. Spratlin
Honoraria - Celgene; Lilly/ImClone; Sanofi
Consulting or Advisory Role - Celgene; Lilly/ImClone; Sanofi
Research Funding - Sanofi